IL-13 is a Th2 cytokine that suppresses the effector function and alters the phenotype and function of macrophages switching to alternatively activated or type II polarized macrophages. The type II polarized macrophages or M2 phenotype differ from normal macrophages greatly in terms of receptor expression, cytokine and NO production, that show tumor promoting function rather than tumoricidal function of classically activated macrophages. The chemokines CCL-22 and CCL-17 produced by either tumor cells or alternatively activated macrophages attract Th2 cells preferentially, which increase the local concentration of Th2 cytokines including IL-13 that further skewed the normal phenotype of macrophages at the site of the tumor micro-environment. Therefore, it is possible to restore the phenotype and function of alternatively activated macrophages by eliminating or blocking the activities of these cytokines. In the present investigation, we show that by blocking the activity/signaling of one of its major constituents IL-13, the iNOS expression and correspondingly NO production increases. The observation signifies its efficacy towards a novel approach for cancer therapy by modulating the function of tumor-associated macrophages (TAM) in vivo for the first time.
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Interleukin (IL)-13 is an anti-inflammatory cytokine produced primarily by activated Th2 cells (1). It is also produced by human naive and memory CD4+ or CD8+T-cells (2) , and exhibits pleiotropic effects on human peripheral blood monocytes and mouse granulocyte-macrophage colony stimulating factor (GM-CSF)-derived bone marrow macrophages (3) . IL-13 has similar effects as IL-4, and both induce morphological and surface Ag changes in human monocytes and inhibit nitric oxide (NO) and pro-inflammatory cytokine production (4) (5) (6) (7) . It up regulates the expression of adhesion molecules and mannose-fucose receptor and the proliferation and migration of various immune cells (8) (9) (10) . In addition, IL-13 induces the expression of various chemokines such as CCL22 (MDC; macrophage-derived chemokines) and CCL 17(TARC; thymus and activation regulated chemokines) that preferentially attract CC-chemokine receptor 4 (CCR4) +T-helper cells, thereby amplifying polarized Th2 response in the tumor-bearing host (11) (12) (13) . This infiltrating Th2 cell in tumor microenvironment increases local concentration of Th2 cytokines including IL-13. Furthermore, tumor cells secrete various soluble factors that effectively inhibit the tumoricidal function of macrophages and favor tumor growth and survival (14) (15) (16) .
Macrophages are most abundant at the Th2 polarizing microenvironment of tumor site, where the function and phenotypes of macrophages change to polarized type II macrophages that differ greatly with classically activated macrophages or M1 phenotype, especially in terms of receptor expression, cytokine and chemokine production (17) (18) . IL-13 is a major constituent in the tumor microenvironment that significantly affects the function and phenotype of macrophages. It has been evidenced that IL-13 alternatively activates the macrophages and induces the arginase pathway for NO production with the generation of ornithine and polyamines that account for low NO production and reduced expression of inducible nitric oxide synthase (iNOS) (19) . Therefore, it is plausible to assume that by eliminating or blocking immunosuppressive soluble factor(s), the function of alternatively activated macrophages can be restored and changed to the phenotype of classically activated macrophages. However, evidence in this regard is completely lacking.
It is evident that IL-13 has two receptor components; IL-13Rul and IL-13Ru2. IL-13 binds strongly to IL-13Rul when present in combination with IL-4Ru and induces IL-13 signaling in the cell (20) (21) . IL-13Ru2 attracts IL-13 avidly, but does not induce signaling, due to very short intracellular domain, and is designated as a decoy receptor (22) . Utilizing the soluble form of IL-13Ru2 chain as an IL-13 inhibitor, the role ofIL-13 in pathophysiology of asthma has been well characterized (23) (24) as similar to the IL-13 blocking by IL-13 mAb (25) . Therefore, in the present investigation, we sought to assess macrophage function in a T-cell lymphoma murine model, in terms of NO production and expression of iNOS, by blocking the activity/ signaling of IL-13.
MATERIALS AND METHODS

Mice and tumor system
Inbred populations of BALB/c (H2") strain of mice of either sex were used at 8 to 12 weeks of age. The mice were given food and water ad libitum under pathogen-free conditions and were treated with utmost human care in an approved animal room facility of the Department of Zoology, Banaras Hindu University. For tumor induction, the healthy mice were injected intraperitoneally with 1.5 x 10 6 DL-cells, a transplantable T-Cell lymphoma of spontaneous origin, in 0.5 ml PBS. The DL-cells for transplantation were obtained from ascitic fluid of DLbearing mice by peritoneal lavage, where the yield of the cells is higher, and maintained in ascitic form in vivo by serial transplantation.
Reagents
Recombinant mouse IL-13 and monoclonal antibody of IL-13 were obtained from Invitrogen Inc., USA. The mouse recombinant IL-13Ru2 (539-1 R) was purchased from R&D System Inc., Mn. The detection antibody conjugated with alkaline phosphatase was obtained from Bangalore Genie, India. Nitro-phenyl phosphate (NPP), Sodium azide (NaN), Diethanolamine and other chemicals were obtained from SRL, India.
Macrophage isolation and culture
Peritoneal macrophages were harvested from normal healthy, control DL-bearing and test group of DL-bearing mice of either sex by a standard method. Macrophages from both groups of mice at 12 days of DL-cell transplantation were harvested by peritoneal lavage using chilled serum-free culture medium RPMI 1640 after killing by pain-free cervical dislocation. Macrophage monolayer was prepared by incubating for 2 h in round plastic petri dishes (Tarson, India) at 37°C in CO 2 incubator. The culture was washed three times with lukewarm serum-free medium with gentle flushing to ensure that all DL-cells and other non-adhering cells were removed. More than 95% of the adhering population was that of macrophages, as determined by morphology and non-specific esterase staining.
The macrophages at 1.0 x 10 5 cells/well were seeded in 96-well flat bottom culture plates (Tarson, India) in RPMI 1640 culture medium supplemented with 10% heat inactivated FCS., 2 mM glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin. The cells were stimulated with 10 ng/ml of LPS for 24 h after pre-treatment in culture medium with or without 0.01 to 20.0 ng/ml IL-13 for 24 h at 37°C in CO 2 incubator, and further experimental analyses were carried out.
Systemic delivery ofIL-13 R a2
A group of 14 DL-bearing mice were injected intraperitoneally (ip.) with 100 ng ofIL-13 Ra2 dissolved in 0.5 ml of sterile PBS at 2 nd day of post-DL-cell transplantation to neutralize systemic IL-13 level in DLbearing mice. At 9 th day of post-DL-cell transplantation, a second dose ofIL-13 Ra2 in 0.5 sterile PBS was given by i.p. injection. After 12 days ofIL-13 Ra2 i.p. injection in DL-bearing mice (test group), macrophages were harvested as described in the previous section. The mice injected only with sterile PBS at the corresponding day of IL-13Ru2 injection were treated as a control group.
Estimation ofnitrite accumulation
Nitrite concentration in culture supernatants was determined by a standard micro plate assay. In brief, 50 III samples were harvested from the conditioned medium and treated with equal volumes of Griess reagent (l % sulfanilamide, 0.1% Naphthalene-ethylene-diamine dihidrochloride and 2.5% H 3P04 ) at room temperature for 10 min. The absorbance at 540 nm was monitored with a micro plate reader (UV/VIS spectrometer, Lambda2, Norwalk, Canada). Nitrite concentration was determined by using Sodium nitrite as a standard. The chemicals used for the preparation of Griess reagent were obtained from Sigma Chemical Co., St. Louis.
Western Blotting
For iNOS gene expression, macrophages (l0 5 ) were lysed in ice-cold buffer containing 25 mM monosodium phosphate (pH 7.4), 75 mM NaCI, 5 mM EDTA, I%Triton X-IOO, l Ouug/ml phenyl methyl sulfonyl _fluoride (Merck), 10 ug/ml Ieupeptin, 10 ug/ml pepstatin, 20 ug/ml aprotinin and 10 ug/ml tyrosine (Sigma Co., St. Louis) inhibitor and centrifuged at 50,000 g for 20 min. at 4°C. The cytosolic proteins (6 ug/lane) were separated by 12% SDS-polyacrylamide gel electrophoresis. Proteins were transferred to nitrocelIulose filter paper and then immunoblotted with rabbit anti-iNOS monoclonal antibody folIowed by incubation with alkaline phosphatase conjugated antibody (Bangalore Genie, India) at a dilution of I :5000. The colour was developed by using nitro blue tetrazoJium reagent as described above.
Statistical Analysis
Each value represents the mean ± SE M of three independent experiments in each group except for in vivo stimulation experiment where two independent experiments were conducted. Data were analyzed by using two-tailed student's t-test on statistical software package Sigma Plot, version 5.0. Differences were considered statisticalIy significant at P < 0.05.
RESULTS
IL-I3 suppresses the production of NO in activated peritoneal macrophages
To assess the IL-13 inhibitory function on NO production of peritoneal macrophages ( NMO), macrophages were pre-treated with IL-13 at different concentration in culture medium for 24 hours and stimulated with LPS ( 10 ng/ml), and it was found that IL-13 inhibits NO production in a dose-dependent manner, as has been reported previously (23) . The LPS-activated macrophages without pre-treatment of IL-13 showed maximal accumulation of N0 2 -in culture medium (26.7 ± 3.84 ulvl), and later with the increasing concentration of IL-13, corresponding suppression of N0 2 -accumulation was observed ( Fig. IA) . The most effective suppression was found with the dose of 10 ng/ml ofIL-13. Consistent with previous observation, macrophages stimulated with LPS (10 ng/ml) in combination with IFN-y (2 ng/ml) showed maximal production of NO and corresponding accumulation of N0 2 -in the culture medium and with higher concentration of IFN-y ( more than 2 ng/ml); the suppressive effects were found to be reduced as per se (data not shown).
TAM from control mice (TAMe) show corresponding suppression ofNO production
The macrophages from DL-bearing mice injected only with sterile PBS were activated with LPS without pretreatment of IL-13 and showed reduced NO production in comparison to macrophages harvested from normal healthy mice (Fig. IA) . The suppressive activity of IL-13 on TAMc seems to be more pronounced in comparison to NMO (normal macrophages) at the same condition which was found to be~84% inhibition (Fig. lB) . This indicates that macrophages in the tumor-microenvironment has altered phenotype and has low responsiveness to LPS with respect to its normal counterpart.Furthermore,the TAMc were incubated with different concentration of IL-13 in the culture medium for 24 hours and thereafter stimulated with 10 ng/ml of LPS a dose dependent inhibition ofN0 2 -accumulation in the culture medium was found, a similar phenomenon as exhibited by normal macrophages (NMO). TAMc pre-incubated with medium alone and activated with LPS showed 37% lower accumulation of N0 2 -with respect to NMO at the same condition. In either case, nonstimulated and without IL-13 pretreated macrophages showed a basal level ofN0 2 -with almost no variation in the culture medium.
TAMfrom treated DL-bearing mice (TAM!) show enhanced production ofNO
To assess the validation of assumption that the elimination or blocking of activity of Th2 cytokines may restore the function of macrophages, we checked it by injecting the DL-bearing mice with soluble non-signaling decoy receptor IL-13 Ra2 to block the activity/signaling of IL-13, as previously we have shown that the DL-bearing mice reflect a high serum as well as ascitic fluid IL-13 level (P. Deepak, et al., unpublished observation). Interestingly, we found that macrophages harvested from treated mice have A.
B . Pre-treatment with IL-13 at different concentrations for 24 hours showed a dose-dependent suppression of NO production ( Fig. 2A) as in the previous case, and maximum suppression was found to be~86.7% at 10 ng/ml of IL-13, more than the TAM harvested from control mice (PBS injected DL-bearing mice) indicating that macrophages are still sensitized to a polarized type II microenvironment. Here we found a significant increase in the release of NO l ' in culture medium, and it was found that LPS-stimulated TAM from treated mice (TAMt) without pre-treatment with IL-13 showed 35.7% enhanced NO l ' accumulation with respect to TAM harvested from untreated or control mice (TAMc) (Fig. 2B) . The increasing concentration of IL-13 showed increased suppression ofNO production in NMO with respect to TAM harvested either from treated mice or control mice.
IL-13 down-regulates iNOS protein synthesis
Further to assess the effect of IL-13 on iNOS protein synthesis in all macrophage types; the macrophages from normal healthy mice, control DL-bearing mice and treated DL-bearing mice were incubated with medium alone or medium containing different concentrations of IL-13 (as indicated) for 24 hours and stimulated with lOng/ml of LPS for another 24 hours, lysed, centrifuged at 4DC and culture supernatants were collected. The supernatants were resolved in 12% polyacrylamide in SDS-PAGE and immunoblotted with iNOS specific mAb. With each case, the iNOS expression was found to be inhibited by IL-1 3. For the NMO (Fig. 3A) , TAM harvested from control mice ( Fig .  38 ) and TAM harve sted from treated mice (Fig. 3C ) showed complete disappearance of iNOS protein in the blot. The iNOS protein was foun d to be expressed at 1.0 ng/ml of fL-13 in TAM from control and treated mice , whereas it appeared in the blo t only after 0.1 ng/ml ofIL-13 in culture medium of normal macro phages, show ing the degree of inhibition of iNOS in phenotypically diffe rent macrophages. The TAM from control mice incubated with medium alone and stimulated with LPS (10 ng/m l) show ed~5 9% appearance in respect to corresponding NMO (taken as 100% in the study). Induction due to IL-13 blocking in TAM harvested from treated mice (TAMt) showed~8 5 % appearance of iNOS protein in the blot (Fig. 4 ) in respect to NMO at same condition.
DISCUSSION
IL-13, a Th2 type cytokine, regulates the function of macrophages (7) and inhibits the expression of iNOS and subsequent production of NO (26) . However, it has been found that IL-13 does not affect the mRNA expression of iNOS protein in peritoneal macrophages, but induces the expression of arginase-I that ultimately affect the L-arginine availability and subsequent inhibition ofde novo synthesis and stability of iNOS protein (27) . Furthermore, the replacement of L-arginine in the culture medium has been found to restore the iNOS protein level and NO production in fL-13 treated macrophages (28) . The suppression of NO production and iNOS protein synthesis in IFN-y/LPS stimulated macrophage cell line J774 (26) and other cell types (29) (30) (31) (32) by IL-13 highlights the potential role in the alteration of macrophage function in Th2 dominating tumor-microenvironment. Our investigation validates the assumption that IL-13 Ra2 treatment induces the nitric oxide production and iNOS protein expression in TAM. Though little work has been done in this regard, the observation is in the line that polarized type II macrophages is not a type of macrophage but alternatively activated phagocyte cell population (33) and that its function can revert back in the Th 1 polarizing cytokine milieu.
Our observation shows that TAM from control mice (PBS injected) respond more actively on pre-treatment of IL-13 than the normal peritoneal resident macrophages (NMO), and shows more reduced production of NO and iNOS protein.
The systemic delivery of soluble IL-I3 Ru2 significantly enhances the production of NO and iNOS protein level in the macrophages. Similar to this observation, inhibitory function of IL-13 can be partially antagonized by increasing concentrations of IFN-y as suggested by the much less impeded production of NO and expression of iNOS in lL-13 treated 1774 macrophages stimulated with much higher concentration of IFN-y (26) . The observation is suggestive of the plasticity of macrophage function in ThI/Th2 microenvironment. On the above account, IL-I3 seems to act as alternative macrophage activator, and IL-13 does not lead to alternatively activated macrophages as totally independent, stable and non-convertible functional states. Though, IL-13 blocking does not completely restore the function of TAM, it only partially, but to a greater extent, restores the function. The partial restoration of function may be due to the fact that in Th2-dominating tumor-microenvironment, several immunosuppressive factors such as IL-4, IL-IO, TGF-p, PGE 2 etc. interact to the macrophages and alter the functional states of macrophages. The high inducing capability ofIL-13 blocking by IL-13Ru2 indicates that their activities are interdependent. However, the mechanism of induction of iNOS expression and NO production in TAM obtained from IL-13Ru2 treated mice is not clear, and further investigation is required. It might be possible that the blocking ofIL-13 activity/signaling inhibits the arginase-I expression (34) by shifting the balance of ThI/Th2 cytokines in the tumor-microenvironment (18, 28, (35) (36) that leads to arginine consumption and reduction in NO production to IFN-y (± LPS) (18, 28, 34) , with (18) or without (28) alteration in the level of iNOS protein, as similar use of an arginase inhibitor during the pre-treatment period prevents the suppression of iNOS protein by IL-13 (27) .
In summary, the IL-13 blocking in the tumor-bearing host, at least in part, restores the tumoricidal functional state of macrophages, and indicates the possibility of completely restoring the function of macrophages by blocking various immunosuppressive interdependent factors at the molecular level. Therefore, it is novel in the sense that it throws light on the possibility of novel anticancer therapeutic approach targeting most-abundant immune cell types at the tumor-microenvironment.
